Claims
- 1. A compound of formula I or Ia:
- 2. A compound of formulae I or Ia of claim 1, wherein:
X is —CR12; m and n are each 0; and p is an integer from 0-2.
- 3. A compound of claim 1 having the following structural formulae II or IIa:
- 4. A compound of claim 3 having the following structural formulae III or IIIa:
- 5. A compound of claim 4 of structural formula III, wherein:
R8 is a methyl group; R12 is H; p is an integer from 1-2; E is a member selected from the group consisting of: 118J is a member selected from the group consisting of: 119G is a member selected from the group consisting of: 120
- 6. A compound of claim 1 having the following structural formulae IV or IVa:
- 7. A compound of claim 6, wherein:
R1, R11 and R14 are each independently selected from the group consisting of hydrogen, methyl, ethyl, —C(═O)OCH2CH3, and —C═(O)OH.
- 8. A compound of claim 6 of formula IV wherein:
q is 0; G is 122A is a member selected from the group consisting of: 123Z is a member selected from the group consisting of: 124n is an integer from 0-2; and D is a member selected from the group consisting of: —O—, —N(CH3)—, and —CH2—.
- 9. A compound of claim 6 having the following structural formula V:
- 10. A compound selected from the group consisting of:
- 11. A pharmaceutical composition for preventing or treating a condition in a mammal characterized by undesired thrombosis comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of one of claims 1-10.
- 12. A method for preventing or treating a condition in a mammal characterized by undesired thrombosis comprising administering to said mammal a therapeutically effective amount of a compound of one of claims 1-10.
- 13. The method of claim 12, wherein the condition is selected from the group consisting of: acute coronary syndrome, myocardial infarction, unstable angina, refractory angina, occlusive coronary thrombus occurring post-thrombolytic therapy or post-coronary angioplasty, a thrombotically mediated cerebrovascular syndrome, embolic stroke, thrombotic stroke, transient ischemic attacks, venous thrombosis, deep venous thrombosis, pulmonary embolus, coagulopathy, disseminated intravascular coagulation, thrombotic thrombocytopenic purpura, thromboangiitis obliterans, thrombotic disease associated with heparin-induced thrombocytopenia, thrombotic complications associated with extracorporeal circulation, thrombotic complications associated with instrumentation such as cardiac or other intravascular catheterization, intra-aortic balloon pump, coronary stent or cardiac valve, and conditions requiring the fitting of prosthetic devices.
- 14. A method for inhibiting the coagulation a biological sample comprising the administration of a compound of one of claims 1-10.
CROSS REFERENCE TO RELATED APPLICATIONS
[0001] This application claims benefit of priority under 35 U.S.C. § 119(e) to U.S. Provisional Application No. 60/191,715 filed on Mar. 24, 2000, which is incorporated here in its entirety by reference.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60191715 |
Mar 2000 |
US |